Nigrostriatal degeneration and serum BDNF levels in patients with “de novo” untreated Parkinson’s disease
Objective: To evaluate serum Brain-Derived NeurotrophicFactor(BDNF) levels in “de novo” untreated Parkinson's disease (PD) patients and their relationship to nigrostriatal degeneration measured with [123I]FP-CIT SPECT.…Dynamic dopamine transporter images are helpful for diagnosing parkinsonism
Objective: This study is aimed at introducing a new method to get Dopamine transporter (DAT) imaging simultaneously with regional cerebral flow (CBF) imaging. Background: DAT…DAT SPECT data of Parkinson’s disease patients with and without REM Sleep Pathology: A report from the DeNoPa cohort
Objective: To evaluate the DAT SPECT (Single photon emission computerized tomography of the dopamine transporter) parameters for Parkinson's disease (PD) patients with REM Sleep Behavior…Relation between the clinical features and the standardized heart to mediastinum ratio in cardiac metaiodobenzylguanidine imaging in patients with Parkinson’s disease: A multicenter cross-sectional study
Objective: To investigate relation between the clinical features and the standardized heart to mediastinum (H/M) ratio by cardiac metaiodobenzylguanidine (MIBG) imaging in patients with Parkinson's…Evidence of striatal dopaminergic dysfunction Sydenham’s chorea in remission with (99m)Tc-TRODAT-1 SPECT
Objective: To report the findings of reduced striatal dopamine transporter (DAT) density in patients with Sydenham's chorea (SC) in remission assessed by single-photon emission computed…Factors affecting the cardiac sympathetic denervation in autopsy confirmed dementia with Lewy bodies
Objective: To examine the relation among degeneration of the cardiac sympathetic nerve (CSN), clinical features and neuropathological findings in dementia with Lewy bodies (DLB). Background:…Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials
Objective: To evaluate subregion-dependent striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants in the Parkinson Progression Marker Initiative (PPMI)…Striatal postsynaptic dysfunction in X-linked dystonia-parkinsonism is associated with disease progression
Objective: To assess pre- and postsynaptic dopaminergic function in X-linked dystonia-parkinsonism (XDP). Background: X-linked dystonia-parkinsonism (XDP) is a neurodegenerative adult-onset movement disorder associated with striatal…Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype
Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…Pisa syndrome in a drug-naive Parkinson’s disease patient
Objective: We report on a patient who presented a reversible Pisa syndrome without any dopaminergic treatment at onset and before diagnosis of Parkinson's disease (PD).…